Home
HelpTest Code IBDP2 Inflammatory Bowel Disease Serology Panel, Serum
Specimen Required
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL Serum
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Secondary ID
610004Useful For
Distinguishing between ulcerative colitis and Crohn disease in patients for whom the specific diagnosis is unclear based on endoscopic, pathologic, and imaging evaluations
This test is not useful for determining the extent of disease in patients with inflammatory bowel disease or determining the response to disease-specific therapy including surgical resection of diseased intestine.
Profile Information
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| ANCA2 | Cytoplasmic Neutrophilic Ab IBD, S | No | Yes |
| SCERA | Saccharomyces cerevisiae Ab, IgA, S | Yes | Yes |
| SCERG | Saccharomyces cerevisiae Ab, IgG, S | Yes | Yes |
Method Name
ANCA2: Indirect Immunofluorescent Assay (IFA)
SCERA, SCERG: Enzyme-Linked Immunosorbent Assay (ELISA)
Reporting Name
Inflammatory Bowel Disease Panel, SSpecimen Type
SerumSpecimen Minimum Volume
Serum: 0.8 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Serum | Refrigerated (preferred) | 21 days |
| Frozen | 21 days |
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | Reject |
| Gross icterus | OK |
| Heat-treated specimen | Reject |
Clinical Information
Inflammatory bowel disease (IBD) refers to 2 diseases, ulcerative colitis (UC) and Crohn disease (CD), both of which result from chronic inflammation in the gastrointestinal (GI) tract.(1) CD is characterized by chronic diarrhea, abdominal pain, and fatigue.(2) In comparison, UC frequently presents with bloody diarrhea that is of an urgent nature.(3) Inflammation in UC most frequently affects the rectum and proximal colon, and presents with continue mucosal involvement. In CD, inflammation can affect almost any area of the GI tract and is usually evidenced as patchy, transmural lesions.
Diagnosis of IBD is primarily based on clinical evaluation, endoscopy with biopsy, and imaging studies.(4) Because CD and UC are characterized by GI inflammation, fecal calprotectin can be used to differentiate IBD from noninflammatory conditions such as irritable bowel syndrome (IBS). Fecal calprotectin is useful in excluding IBD as a diagnosis and avoiding unnecessary endoscopic or imaging procedures.
Both CD and UC are associated with the presence of various antimicrobial and autoantibodies.(5,6) Patients with UC often have measurable antineutrophil cytoplasmic antibodies (ANCA), which react with as yet uncharacterized target antigens in human neutrophils; in contrast, patients with CD often have measurable IgA and/or IgG antibodies, which react with cell wall mannan of Saccharomyces cerevisiae. Despite these associations, current guidelines indicate that testing for these antibodies is not sufficiently sensitive for use in the diagnosis of IBD.(2,3) Rather, these antibodies should be limited to distinguishing between CD and UC in cases where the specific diagnosis is unclear based on pathologic and imaging studies.
Reference Values
CYTOPLASMIC NEUTROPHIL ANTIBODIES, INFLAMMATORY BOWEL DISEASE PANEL, SERUM
Negative (not detectable)
SACCHAROMYCES CEREVISIAE ANTIBODY, IGA
Negative: <20.0 RU/mL
Positive: ≥20.0 RU/mL
SACCHAROMYCES CEREVISIAE ANTIBODY, IGG
Negative: <20.0 RU/mL
Positive: ≥20.0 RU/mL
Interpretation
The presence of antineutrophil cytoplasmic antibodies in the absence of IgA and IgG anti-Saccharomyces cerevisiae antibodies is consistent with the diagnosis of ulcerative colitis; the presence of IgA and IgG ASCA in the absence of ANCA is consistent with Crohn disease.
Cautions
Results from this test should not be exclusively relied upon to establish the diagnosis of ulcerative colitis (UC) or Crohn disease (CD) or to distinguish between these 2 diseases.
Some patients with CD have detectable antineutrophil cytoplasmic antibodies (ANCA), and some patients with UC have detectable IgA and/or IgG anti-Saccharomyces cerevisiae antibodies (ASCA). Some patients with UC or CD do not have detectable ANCA, IgA ASCA, or IgG ASCA.
ANCA results may be reported as indeterminate if interfering antinuclear antibodies (ANA) are present.
Clinical Reference
1. Rose NR, Mackay IR, eds. Inflammatory bowel diseases. In: The Autoimmune Diseases: Elsevier; 2008
2. Lichtenstein GR, Loftus EV, Afzali A, et al. ACG clinical guideline: Management of Crohn's disease in adults. Am J Gastroenterol. 2025;120(6):1225-1264
3. Rubin DT, Ananthakrishnan AN, Siegel CA, Barnes EL, Long MD. ACG Clinical Guideline Update: Ulcerative Colitis in Adults. Am J Gastroenterol. 2025;120(6):1187-1224
4. Clark C, Turner J. Diagnostic modalities for inflammatory bowel disease: Serologic markers and endoscopy. Surg Clin North Am. 2015;95(6):1123-1141
5. Zhou G, Song Y, Yang W, et al. ASCA, ANCA, ALCA and many more: Are they useful in the diagnosis of inflammatory bowel disease? Dig Dis. 2016;34(1-2):90-97. doi:10.1159/000442934
6. Sendid B, Cornu M, Cordier C, Bouckaert J, Colombel JF, Poulain D. From ASCA breakthrough in Crohn's disease and Candida albicans research to thirty years of investigations about their meaning in human health. Autoimmun Rev. 2024;23(2):103486
Method Description
Testing for antineutrophil cytoplasmic antibodies is performed using a laboratory-developed immunoassay.(Unpublished Mayo method)
Testing for IgA and IgG anti-Saccharomyces cerevisiae antibodies is performed using a laboratory-developed immunoassay.(Unpublished Mayo method)
Day(s) Performed
Monday through Friday
Report Available
3 to 7 daysSpecimen Retention Time
14 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
86671 x 2
86036
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| IBDP2 | Inflammatory Bowel Disease Panel, S | 87551-8 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 610030 | Cytoplasmic Neutrophilic Ab IBD, S | 17355-9 |
| SCERA | Saccharomyces cerevisiae Ab, IgA, S | 47320-7 |
| SCERG | Saccharomyces cerevisiae Ab, IgG, S | 47321-5 |
| 614542 | ANCA2 Interpretation | 49308-0 |
Forms
If not ordering electronically, complete, print, and send Gastroenterology and Hepatology Test Request (T728) with the specimen.
Testing Algorithm
For more information see the following:
-Inflammatory Bowel Disease Diagnostic Testing Algorithm
-Ulcerative Colitis and Crohn Disease Therapeutic Drug Monitoring Algorithm